Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX

Contributed by: Business Wire

Tags

Stem Cells

Medical Supplies

Biotechnology

Other Health

Health

Pharmaceutical

Health Technology

Research

Genetics

Science

Clinical Trials

allergy

More Like This

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.